122 related articles for article (PubMed ID: 9368196)
1. Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects.
Seifritz E; Müller MJ; Annen O; Nil R; Hatzinger M; Hemmeter U; Moore P; Holsboer-Trachsler E
J Psychiatr Res; 1997; 31(5):543-54. PubMed ID: 9368196
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral racemic citalopram on neuroendocrine responses.
Hawken ER; Owen JA; Van Vugt D; Delva NJ
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):694-700. PubMed ID: 16563590
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine effects of citalopram infusion in anorexia nervosa.
Mondelli V; Gianotti L; Picu A; Abbate Daga G; Giordano R; Berardelli R; Pariante CM; Fassino S; Ghigo E; Arvat E
Psychoneuroendocrinology; 2006 Nov; 31(10):1139-48. PubMed ID: 17045409
[TBL] [Abstract][Full Text] [Related]
4. Low-dose citalopram as a 5-HT neuroendocrine probe.
Attenburrow MJ; Mitter PR; Whale R; Terao T; Cowen PJ
Psychopharmacology (Berl); 2001 May; 155(3):323-6. PubMed ID: 11432696
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
Nadeem HS; Attenburrow MJ; Cowen PJ
Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
[TBL] [Abstract][Full Text] [Related]
6. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests.
Henning J; Netter P
Int J Neuropsychopharmacol; 2002 Mar; 5(1):67-71. PubMed ID: 14609009
[TBL] [Abstract][Full Text] [Related]
7. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI.
Lowe SL; Yeo KP; Teng L; Soon DK; Pan A; Wise SD; Peck RW
Psychoneuroendocrinology; 2006 May; 31(4):473-84. PubMed ID: 16378695
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans.
Berardelli R; Margarito E; Ghiggia F; Picu A; Balbo M; Bonelli L; Giordano R; Karamouzis I; Bo M; Ghigo E; Arvat E
J Endocrinol Invest; 2010 Oct; 33(9):657-62. PubMed ID: 20414043
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of serotoninergic challenge with oral citalopram.
Mattos P; Franco VA; Noel F; Segenreich D; Gonçalves JC
Braz J Psychiatry; 2006 Sep; 28(3):203-5. PubMed ID: 17063220
[TBL] [Abstract][Full Text] [Related]
10. Specific effects of escitalopram on neuroendocrine response.
Hawken ER; Owen JA; Hudson RW; Delva NJ
Psychopharmacology (Berl); 2009 Nov; 207(1):27-34. PubMed ID: 19662384
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.
Lotrich FE; Bies R; Muldoon MF; Manuck SB; Smith GS; Pollock BG
Psychopharmacology (Berl); 2005 Mar; 178(2-3):268-75. PubMed ID: 15365685
[TBL] [Abstract][Full Text] [Related]
12. Infusion of a lipid emulsion in healthy men decreases the serotonergic response.
Sondermeijer BM; Klein Twennaar CF; Kastelein JJ; Franssen EJ; Hutten BA; Dallinga-Thie GM; Stroes ES; Fliers E; Twickler MT; Serlie MJ
Neuroendocrinology; 2012; 95(4):325-31. PubMed ID: 22327404
[TBL] [Abstract][Full Text] [Related]
13. The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls.
Kilkens TO; Honig A; Fekkes D; Brummer RJ
Aliment Pharmacol Ther; 2005 Nov; 22(9):865-74. PubMed ID: 16225497
[TBL] [Abstract][Full Text] [Related]
14. Citalopram challenge in social anxiety disorder.
Shlik J; Maron E; Tru I; Aluoja A; Vasar V
Int J Neuropsychopharmacol; 2004 Jun; 7(2):177-82. PubMed ID: 14741063
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course.
Markianos M; Hatzimanolis J; Lykouras L
Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):172-6. PubMed ID: 12242578
[TBL] [Abstract][Full Text] [Related]
16. Acute hormonal changes after IV citalopram and treatment response in OCD.
Corregiari FM; Gattaz WF; Bernik M
Psychopharmacology (Berl); 2007 Sep; 193(4):487-94. PubMed ID: 17492272
[TBL] [Abstract][Full Text] [Related]
17. The citalopram challenge test in patients with major depression and in healthy controls.
Kapitany T; Schindl M; Schindler SD; Hesselmann B; Füreder T; Barnas C; Sieghart W; Kasper S
Psychiatry Res; 1999 Nov; 88(2):75-88. PubMed ID: 10622344
[TBL] [Abstract][Full Text] [Related]
18. State and trait abnormalities in serotonin function in major depression.
Bhagwagar Z; Whale R; Cowen PJ
Br J Psychiatry; 2002 Jan; 180():24-8. PubMed ID: 11772847
[TBL] [Abstract][Full Text] [Related]
19. S-Citalopram in neuroendocrine challenge-tests: serotonergic responsivity in healthy male and female human participants.
Kuepper Y; Bausch S; Iffland J; Reuter M; Hennig J
Psychoneuroendocrinology; 2006 Nov; 31(10):1200-7. PubMed ID: 17123742
[TBL] [Abstract][Full Text] [Related]
20. Lower central serotonergic responsivity is associated with preclinical carotid artery atherosclerosis.
Muldoon MF; Mackey RH; Sutton-Tyrrell K; Flory JD; Pollock BG; Manuck SB
Stroke; 2007 Aug; 38(8):2228-33. PubMed ID: 17626900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
